We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Benign Hematology

Journal Scan / Research · November 15, 2021

Clonal Hematopoiesis and Secondary Myeloid Neoplasms in High-Grade Ovarian Cancer Treated With Rucaparib

JAMA Oncology


Additional Info

JAMA Oncology
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
JAMA Oncol 2021 Oct 14;[EPub Ahead of Print], TT Kwan, AM Oza, AV Tinker, I Ray-Coquard, A Oaknin, C Aghajanian, D Lorusso, N Colombo, A Dean, J Weberpals, E Severson, LT Vo, S Goble, L Maloney, T Harding, SH Kaufmann, JA Ledermann, RL Coleman, IA McNeish, KK Lin, EM Swisher

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading